Advisors Capital Management LLC Lowers Stake in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Advisors Capital Management LLC reduced its holdings in Regeneron Pharmaceuticals by **46.5%**, selling 801 shares and now owning 921 shares valued at **$584,000**.
• Regeneron Pharmaceuticals reported **$12.89 EPS** for the last quarter, exceeding the consensus estimate by **$4.46**, with revenues of **$3.68 billion**, which was above analyst expectations.
• The company declared a quarterly dividend of **$0.88**, representing an annualized yield of **0.6%** and a dividend payout ratio of **8.87%**.

Advisors Capital Management LLC trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 46.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 921 shares of the biopharmaceutical company's stock after selling 801 shares during the quarter. Advisors Capital Management LLC's holdings in Regeneron Pharmaceuticals were worth $584,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Pinney & Scofield Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. raised its position in shares of Regeneron Pharmaceuticals by 344.4% in the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 31 shares in the last quarter. Activest Wealth Management raised its position in shares of Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 21 shares in the last quarter. Costello Asset Management INC bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth $27,000. Finally, Saudi Central Bank bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth $27,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on REGN shares. Guggenheim boosted their price target on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Redburn Atlantic upgraded Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Argus lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Rothschild & Co Redburn assumed coverage on Regeneron Pharmaceuticals in a report on Thursday, August 14th. They issued a "buy" rating and a $890.00 price target for the company. Finally, Morgan Stanley restated an "overweight" rating and set a $761.00 price objective (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Three analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $817.67.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded up $2.47 during trading hours on Tuesday, hitting $575.06. The company's stock had a trading volume of 707,913 shares, compared to its average volume of 1,094,070. The stock has a market cap of $60.95 billion, a PE ratio of 14.49, a price-to-earnings-growth ratio of 1.87 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,165.85. The company has a 50 day moving average of $565.30 and a 200 day moving average of $577.02. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. The company had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm's quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the firm posted $11.56 earnings per share. On average, sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.